Mealey's (April 14, 2023, 9:11 AM EDT) -- WASHINGTON, D.C. — In a supplemental brief filed in response to the U.S. government’s amicus curiae brief supporting a generic drugmaker’s petition for certiorari, GlaxoSmithKline LLC (GSK) accuses the government of rewriting the facts of the underlying case, as well as the federal “carve-out” process by which generic versions of patented drugs receive approval....